Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC101 for Resistant Hypertension in Moderate to Severe CKD
NCT07483372Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC-101 in resistant hypertension (RH), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 364. Started Mar 2026; status: recruiting.
02
Drugs
SC-101
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07483372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483372.